primaquine + sulfadoxine + pyrimethamine + artesunate

This is a four-drug antimalarial combination consisting of primaquine, sulfadoxine, pyrimethamine, and artesunate. Each component has a distinct mechanism of action targeting different stages or aspects of the malaria parasite's lifecycle: - **Primaquine** is an 8-aminoquinoline that targets liver-stage hypnozoites and gametocytes, helping to prevent relapse and reduce transmission. - **Sulfadoxine** is a sulfonamide that inhibits dihydropteroate synthase in the folate synthesis pathway. - **Pyrimethamine** is a diaminopyrimidine that inhibits dihydrofolate reductase in the same pathway; together with sulfadoxine, it acts synergistically to block folate metabolism essential for parasite DNA synthesis. - **Artesunate** is an artemisinin derivative that rapidly kills blood-stage parasites by generating reactive oxygen species. This combination would theoretically provide rapid clearance of blood-stage parasites (artesunate), prevention of relapse (primaquine), reduction in transmission (primaquine), and sustained suppression through inhibition of folate metabolism (sulfadoxine-pyrimethamine). While combinations such as artesunate plus sulfadoxine-pyrimethamine are used for uncomplicated malaria[9][7][8], there are no standard regimens or clinical trial data supporting the use of all four drugs together as a single fixed-dose combination. However, each component has been studied extensively in various two- or three-drug combinations for Plasmodium falciparum and Plasmodium vivax malaria[3][7][9].